Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Century Therapeutics, Inc. due to higher revenues, but actual results compared to estimates will significantly influence the stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.31 per share, reflecting a year-over-year change of +31.1% [3]. - Revenues are projected to be $45.52 million, representing a substantial increase of 5193% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.86% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Century Therapeutics is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -30.43% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8]. Historical Performance - In the last reported quarter, Century Therapeutics was expected to post a loss of $0.45 per share but delivered a loss of $0.43, resulting in a surprise of +4.44% [12]. - The company has beaten consensus EPS estimates in the last four quarters [13]. Conclusion - Century Therapeutics does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].